Adicet Bio reports early CAR-T therapy improves lupus symptoms, plans pivotal trial as shares fall

Adicet Bio said its off-the-shelf CAR-T cell therapy showed signs of efficacy in a small early-stage trial involving patients with systemic lupus erythematosus.

The study reported measurable improvements in disease symptoms, prompting the company to announce plans to launch a larger, pivotal trial later this year.

Despite the encouraging data, the company's shares declined after the announcement, reflecting investor concerns about the early stage of development and the challenges of bringing a novel cell therapy to market.